Medical News

RSS

Health Union releases results of 'Migraine In America 2012' study

Health Union, LLC, released the results of its landmark study "Migraine In America 2012" tonight via a live web conference.

31 Jul 2012

Depomed submits Serada NDA with FDA for treatment of menopausal hot flashes

Depomed, Inc. today announced that it has submitted a New Drug Application (NDA) for Serada to the United States Food and Drug Administration. Serada is Depomed's proprietary extended release formulation of gabapentin in development for the treatment of menopausal hot flashes.

31 Jul 2012

Array BioPharma announces positive results from ARRY-797 Phase 2 trial on osteoarthritis

Array BioPharma today announced that ARRY-797 met its primary endpoint in a randomized, placebo-controlled and active-controlled (oxycodone ER) Phase 2 clinical trial in 157 osteoarthritis patients suffering from moderate to severe knee pain despite the use of non-steroidal anti-inflammatory drugs (NSAIDs).

31 Jul 2012

Ventas prices public offering of $275 million of 3.25% Senior Notes due 2022

Ventas, Inc. announced today that it has priced a public offering of $275 million aggregate principal amount of 3.25% Senior Notes due 2022 at 99.027% of principal amount.

31 Jul 2012

Rye Radiology offers new 3D mammography that detects many breast cancers

Rye Radiology Associates, LLP, became the first facility between Manhattan and Syracuse to offer the new FDA-approved 3D mammography which finds more breast cancers than traditional mammography.

31 Jul 2012

FibroGen receives FDA Orphan Drug Designation for FG-3019 to treat IPF

FibroGen, Inc., today announced that FG-3019, the Company's human monoclonal antibody against connective tissue growth factor (CTGF), has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of idiopathic pulmonary fibrosis (IPF).

31 Jul 2012

Affymetrix second quarter total revenue increases to $66.4 million

Affymetrix, Inc., today reported its operating results for the second quarter of 2012. Total revenue for the quarter was $66.4 million, including approximately $1.4 million in revenue from eBioscience following the close of Affymetrix's acquisition of the company on June 25. This compares to total revenue of $64.7 million for the same period of 2011.

31 Jul 2012

Alseres enters agreement with Navidea to license Altropane imaging agent

Alseres Pharmaceuticals, Inc. today announced that it has entered into an agreement with Navidea Biopharmaceuticals, Inc. to license, [123I]-E-IACFT Injection (CFT), also called Altropane, an Iodine-123 radiolabeled imaging agent, being developed as an aid in the diagnosis of Parkinson's disease and movement disorders.

31 Jul 2012

Australia's top medical researchers for 2012 announced

Finalists for one of Australia’s longest running and most prestigious awards for medical research were announced today. This year’s winner will join a list of alumni winners that includes many of the country’s most respected scientists.

31 Jul 2012

Population Genetics validates GenomePooling™ for cancer

Population Genetics Technologies Ltd., creator of innovative methods for genetic analyses and biomarker discovery, has successfully completed a pilot study to prove that its GenomePooling™ method is sensitive and accurate enough to detect even small percentages of gene variants within cancer tissue. This validates the method’s suitability for use in IntReALL 2010, the world’s largest genetic analysis of acute lymphoblastic leukaemia (ALL) relapse cases. ALL is the most common childhood malignant disease.

31 Jul 2012

E-nose detects malignant mesothelioma

Australian researchers have developed a breath test using an electronic nose to help diagnose malignant mesothelioma in its early stages, a potentially life-saving move.

31 Jul 2012

ICF receives IDIQ contract to conduct pilot and evaluation studies, statistical analysis and TTA

ICF International, a leading provider of consulting services and technology solutions to government and commercial clients, has been awarded a re-compete multiple-award Indefinite Delivery Indefinite Quantity (IDIQ) contract by the U.S. Department of Health and Human Services (HHS), Substance Abuse and Mental Health Services Administration (SAMHSA) to conduct pilot and evaluation studies, statistical analysis, and training and technical assistance (TTA).

31 Jul 2012

IPS examines progress on HIV/AIDS in the Caribbean

Inter Press Service reports on HIV/AIDS in the Caribbean, a region with "the second highest incidence of HIV/AIDS after sub-Saharan Africa." The news service highlights a report, titled "Together We Will End AIDS" and released by UNAIDS ahead of the XIX International AIDS Conference (AIDS 2012) in Washington, D.C., last week, that "noted that AIDS-related deaths in the Caribbean have declined by almost 50 percent in 10 years."

31 Jul 2012

Opioid receptors can control metabolic response to diets high in fat and sugar

Imagine eating all of the sugar and fat that you want without gaining a pound. Thanks to new research published in The FASEB Journal, the day may come when this is not too far from reality.

31 Jul 2012

High choline intake during pregnancy may improve how a child responds to stress

If you're sick from stress, a new research report appearing in the August 2012 issue of The FASEB Journal suggests that what your mother ate-or didn't eat-may be part of the cause.

31 Jul 2012

Researchers use computational analysis to identify new Achilles heel for drug-resistant breast cancer

Researchers have used computational analysis to identify a new Achilles heel for the treatment of drug-resistant breast cancer. The results, which are published in Molecular Systems Biology, reveal that the disruption of glucose metabolism is an effective therapeutic strategy for the treatment of tumours that have acquired resistance to front-line cancer drugs such as Lapatinib.

31 Jul 2012

GenSpera receives FDA clearance to commence G-202 Phase II trial in prostate cancer

GenSpera, Inc. announced that the U.S. Food and Drug Administration (FDA) has cleared for initiation a Phase II human clinical trial of its lead compound, G-202, in the treatment of prostate cancer patients who have failed prior hormonal therapy.

31 Jul 2012

Researchers identify anxiety as important risk factor for long-term sick leave

Long-term sick leave is a burden for individuals and society at large, yet very little is known about the underlying reasons for it. Researchers at the Norwegian Institute of Public Health, in collaboration with Australian and British institutes, have identified anxiety as a more important risk factor than previously thought.

31 Jul 2012

Study examines link between early-onset mental disorders and adult household income

Mental disorders that emerge in childhood and adolescence, including attention-deficit disorder, depression, anxiety and substance abuse, constitute significant challenges to cognitive, emotional, and social development.

31 Jul 2012

Latrepirdine appears effective in treating Alzheimer's disease in animals

An international team of scientists led by researchers at Mount Sinai School Medicine have discovered that a drug that had previously yielded conflicting results in clinical trials for Alzheimer's disease effectively stopped the progression of memory deterioration and brain pathology in mouse models of early stage Alzheimer's disease.

31 Jul 2012